Funding for this research was provided by:
Fundación María Cristina Masaveu Peterson
Universidad de Oviedo
Received: 20 March 2018
Accepted: 14 June 2018
First Online: 9 July 2018
Ethics approval and consent to participate
: The study was approved by the Comité de Ética de Investigación del Principado de Asturias (research project #75/14). Consent was obtained from all patients or their parents.
: Not applicable.
: The following authors are currently employed by IMOMA or DREAMgenics, the companies involved in the development and exploitation of the OTOgenics™ platform: IMOMA: Ru.C. (Physician in Chief), M.D. (Clinical Molecular Geneticist), G.A.C. (Biotechnologist), N.S.D. (Lab. Technician), R.A. (Lab. Technician), Ra.C. (Molecular Biologist) and J.C. (Scientific Director); DREAMgenics: D.C. (Bioinformatitian), P.C.P. (Bioinformatitian) and G.R.O. (Bioinformatitian, C.S.O. and C.E.O.). G.R.O. is a shareholder of DREAMgenics. The other authors declare no conflict of interest.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.